Chronic Migraine
Conditions
Brief summary
The purpose of this study is to study MIGRA-ZEN RELIEF PLUS, an all-natural herbal dietary supplement product, with respect to alleviating and/or stopping migraine headache pain compared to a placebo when used prophylactically. This study will involve subjects suffering from chronic migraine headaches.
Detailed description
The purpose of this 90-day, randomized, double-blind, placebo controlled study is to evaluate the efficacy of an all-natural herbal dietary supplement product, (Investigational Product, or IP), with respect to alleviating and/or stopping migraine headache pain compared to a placebo when used prophylactically every day, and to evaluate the safety/risk of its use by observing the absence/presence of adverse event (AE/SAE) reports and the normalcy of blood work, urinalysis, and liver enzyme tests. The primary end-point is the time-course and depth of the frequency reduction of migraine attacks. The secondary end-points will be the absence/presence of detectable adverse liver function and urinalysis test results as well as the dearth/abundance of AE/SAE reports that may indicate patient safety/risk when using the IP.
Interventions
DIETARY_SUPPLEMENTMIGRA-ZEN RELIEF PLUS
one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
DIETARY_SUPPLEMENTPlacebo for Migrazen relief plus
2 capsule dose per 24 hours for 90 days
Sponsors
RZN Nutraceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female subjects 18 years of age or older. * Prior to this study subject must have been diagnosed with migraines according to IHS criteria by a qualified healthcare professional with some experience in the diagnosis of migraines and have suffered with them for one year prior to the start of the study. * Migraine symptoms/attacks must have presented for a minimum of the last consecutive three (3) months at a minimum average frequency of six (6) times per month and must have been severe-extreme (grade 7-10) on a linear scale of 0-10, where 0=no pain and 10=unbearable maximum pain. * Subjects who are able to follow the protocol as designed by RZN Nutraceuticals, Inc. and Teva Pharmaceutical Industries. * Generally good health
Exclusion criteria
* Subjects currently taking any prophylactic treatment for migraine headaches * History of head trauma or brain cancer. * Candidate subjects with any medical condition that, in the opinion of the investigators or intake staff, would jeopardize the safety of the patient, affect the validity of the data collected from the subject, or would challenge the subject's ability to complete the study protocol for 90 days. * Known renal insufficiency or kidney disease of any grade * Any illness causing severe coughing so as to avoid introducing coughing migraine per IHS classification 4.2, G44.803. * History of drug addiction. * Females of child-bearing potential who do not practice medically acceptable methods of contraception surgical, sterilization, intrauterine device (IUD), hormonal preparations or double barrier method (e.g. condom or diaphragm and spermicide) * Subjects with uncontrolled hypertension (e.g. BP\>150/100).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The reduction of migraine attacks | 90 Days | The time-course and depth of the frequency in the reduction of migraine attacks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AEs SAEs | 90 days | The secondary end-points will be the absence/presence of detectable adverse liver function and urinalysis test results as well as the dearth/abundance of AE/SAE reports that may indicate patient safety/risk when using the IP. |
Countries
Israel
Contacts
Primary ContactMark Lubin, MD
Outcome results
None listed